Anthony S. Marucci - Aug 15, 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
PRESIDENT & CEO, Director
Signature
/s/ Samuel B. Martin, attorney-in-fact for Anthony S. Marucci
Stock symbol
CLDX
Transactions as of
Aug 15, 2022
Transactions value $
-$3,905,330
Form type
4
Date filed
8/17/2022, 04:06 PM
Previous filing
Jun 17, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $209K +75K +270.84% $2.78* 103K Aug 15, 2022 Direct F1
transaction CLDX Common Stock Options Exercise $406K +45K +43.82% $9.02 148K Aug 15, 2022 Direct F2
transaction CLDX Common Stock Sale -$4.52M -120K -81.25% $37.66 27.7K Aug 15, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -75K -75% $0.00 25K Aug 15, 2022 Common Stock 75K $2.78 Direct F4
transaction CLDX Incentive Stock Option Options Exercise $0 -45K -62.79% $0.00 26.7K Aug 15, 2022 Common Stock 45K $9.02 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F2 This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 As of June 13, 2022, the option is fully vested.